What’s Fueling AI’s Growth

It’s no secret that the rapid growth of AI in radiology is being fueled by venture capital firms eager to see a payoff for early investments in startup AI developers. But are there signs that VCs’ appetite for radiology AI is starting to wane?

Maybe. And maybe not. While one new analysis shows that AI investments slowed in 2023 compared to the year before, another predicts that over the long term, VC investing will spur a boom in AI development that is likely to transform radiology. 

First up is an update by Signify Research to its ongoing analysis of VC funding. The new numbers show that through Q3 2023, the number of medical imaging AI deals has fallen compared to Q3 2022 (24 vs. 40). 

  • Total funding has also fallen for the second straight year, to $501M year-to-date in 2023. That compares to $771M through the third quarter of 2022, and $1.1B through the corresponding quarter of 2021. 

On the other hand, the average deal size has grown to an all-time high of $20.9M, compared to 2022 ($15.4M) and 2021 ($18M). 

  • And one company – Rapid AI – joined the exclusive club of just 14 AI vendors that have raised over $100M with a $75M Series C round in July 2023. 

In a look forward at AI’s future, a new analysis in JACR by researchers from the ACR Data Science Institute (DSI) directly ties VC funding to healthcare AI software development, predicting that every $1B in funding translates into 11 new product approvals, with a six-year lag between funding and approval. 

  • And the authors forecast long-term growth: In 2022 there were 69 FDA-approved products, but by 2035, funding is expected to reach $31B for the year, resulting in the release of a staggering 350 new AI products that year.

Further, the ACR DSI authors see a virtuous cycle developing, as increasing AI adoption spurs more investment that creates more products available to help radiologists with their workloads. 

The Takeaway

The numbers from Signify and ACR DSI don’t match up exactly, but together they paint a picture of a market segment that continues to enjoy massive VC investment. While the precise numbers may fluctuate year to year, investor interest in medical imaging AI will fuel innovation that promises to transform how radiology is practiced in years to come.

AI Investment Shift

VC investment in the AI medical imaging sector has shifted notably in the last couple years, says a new report from UK market intelligence firm Signify Research. The report offers a fascinating look at an industry where almost $5B has been raised since 2015. 

VC investment in the AI medical imaging sector has shifted in the last couple years, with money moving to later-stage companies.

Total Funding Value Drops – Both investors and AI independent software vendors (ISVs) have noticed reduced funding activity, and that’s reflected in the Signify numbers. VC funding of imaging AI firms fell 32% in 2022, to $750.4M, down from a peak of $1.1B in 2021.

Deal Volume Declines – The number of deals getting done has also fallen, to 42 deals in 2022, off 30% compared to 60 in 2021. In imaging AI’s peak year, 2020, 95 funding deals were completed. 

VC Appetite Remains Strong – Despite the declines, VCs still have a strong appetite for radiology AI, but funding has shifted from smaller early-stage deals to larger, late-stage investments. 

HeartFlow Deal Tips Scales – The average deal size has spiked this year to date, to $27.6M, compared to $17.9M in 2022, $18M in 2021, and $7.9M in 2020. Much of the higher 2023 number is driven by HeartFlow’s huge $215M funding round in April; Signify analyst Sanjay Parekh, PhD, told The Imaging Wire he expects the average deal value to fall to $18M by year’s end.

The Rich Get Richer – Much of the funding has concentrated in a dozen or so AI companies that have raised over $100M. Big winners include HeartFlow (over $650M), and Cleerly, Shukun Technology, and Viz.ai (over $250M). Signify’s $100M club is rounded out by Aidoc, Cathworks, Keya Medical, Deepwise Shenrui, Imagen Technologies, Perspectum, Lunit, and Annalise.ai.

US and China Dominate – On a regional basis, VC funding is going to companies in the US (almost $2B) and China ($1.1B). Following them are Israel ($513M), the UK ($310M), and South Korea ($255M).  

The Takeaway 

Signify’s report shows the continuation of trends seen in previous years that point to a maturing market for medical imaging AI. As with any such market, winners and losers are emerging, and VCs are clearly being selective about choosing which horses to put their money on.

Get every issue of The Imaging Wire, delivered right to your inbox.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Imaging Wire team

You're all set!